Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849984 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL27051202 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL13427508 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL887485 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL8860350 | 0.98 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL334143 | 0.94 | SLC6A11 (0.48) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL26415000 | 0.93 | SLC6A11 (0.44) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL8327519 | 0.92 | KIF11 (0.42) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL19437634 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL20915040 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135669-A1 | SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. | 2011-06-09 | — | — | US | disclosed |
| US-7884197-B2 | Synthetic agonists of TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2079305-A2 | SYNTHETIC AGONISTS OF TLR9 | Idera Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080292648-A1 | SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008073959-A2 | SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292648-A1 | SYNTHETIC AGONISTS OF TLR9 | TLR9, TLR3, TLR7 | SLC6A11 4722/4885SLC6A1 4756/4885KIF11 3670/4885 |
| US-20110135669-A1 | SYNTHETIC AGONISTS OF TLR9 | TLR9, TLR3, TLR7 | SLC6A11 4722/4885SLC6A1 4756/4885KIF11 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.